Mesoblast Ltd has a consensus price target of $0.58 based on the ratings of 16 analysis. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Cantor Fitzgerald, and Piper Sandler on September 21, 2023, August 31, 2023, and August 4, 2023, respectively. With an average price target of $12 between Cantor Fitzgerald, Cantor Fitzgerald, and Piper Sandler, there's an implied 57.27% upside for Mesoblast Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
06/04/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
09/21/2023 | Buy Now | 122.8% | Cantor Fitzgerald | Louise Chen | → $68 | Reiterates | Overweight → Overweight | Get Alert |
08/31/2023 | Buy Now | — | Jefferies | David Stanton | — | Upgrade | Hold → Buy | Get Alert |
08/31/2023 | Buy Now | 122.8% | Cantor Fitzgerald | Louise Chen | $92 → $68 | Maintains | Overweight | Get Alert |
08/07/2023 | Buy Now | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
08/04/2023 | Buy Now | — | William Blair | Sami Corwin | — | Downgrade | Outperform → Market Perform | Get Alert |
08/04/2023 | Buy Now | -73.79% | Piper Sandler | Edward Tenthoff | $28 → $8 | Downgrade | Overweight → Neutral | Get Alert |
08/04/2023 | Buy Now | -80.34% | Chardan Capital | Keay Nakae | $8 → $6 | Maintains | Sell | Get Alert |
05/30/2023 | Buy Now | -73.79% | Chardan Capital | Keay Nakae | $10 → $8 | Maintains | Sell | Get Alert |
03/01/2023 | Buy Now | -67.23% | Chardan Capital | Keay Nakae | → $10 | Reiterates | → Sell | Get Alert |
02/01/2023 | Buy Now | 201.44% | Cantor Fitzgerald | Louise Chen | → $92 | Reiterates | → Overweight | Get Alert |
12/06/2022 | Buy Now | — | Jefferies | David Stanton | — | Downgrade | Buy → Hold | Get Alert |
09/06/2022 | Buy Now | -8.26% | Piper Sandler | Edward Tenthoff | → $28 | Initiates | → Overweight | Get Alert |
06/03/2022 | Buy Now | -67.23% | Chardan Capital | Keay Nakae | $26 → $10 | Maintains | Sell | Get Alert |
08/31/2021 | Buy Now | -14.81% | Chardan Capital | Keay Nakae | $30 → $26 | Maintains | Sell | Get Alert |
The latest price target for Mesoblast (NASDAQ:MESO) was reported by Cantor Fitzgerald on June 20, 2024. The analyst firm set a price target for $0.00 expecting MESO to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Mesoblast (NASDAQ:MESO) was provided by Cantor Fitzgerald, and Mesoblast reiterated their overweight rating.
The last upgrade for Mesoblast Ltd happened on August 31, 2023 when Jefferies raised their price target to N/A. Jefferies previously had a hold for Mesoblast Ltd.
The last downgrade for Mesoblast Ltd happened on August 7, 2023 when Maxim Group changed their price target from N/A to N/A for Mesoblast Ltd.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mesoblast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mesoblast was filed on June 20, 2024 so you should expect the next rating to be made available sometime around June 20, 2025.
While ratings are subjective and will change, the latest Mesoblast (MESO) rating was a reiterated with a price target of $0.00 to $0.00. The current price Mesoblast (MESO) is trading at is $7.63, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.